ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IRD / news
BNTC (30) PRLD (33) VOGX (45) ENTA (20) ⌘ Pro Terminal →

Why IRD Stock advanced +0.82% Today — RQD Quant Desk Flash

$3.70 +0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.70

Opus Genetics Inc. (IRD) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $305.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Opus Genetics Inc. (NASDAQ: IRD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $3.70 (+0.82% 1D, market cap $305.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IRD ranks #945 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRD compare to BNTC and PRLD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRD carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $304.9M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, IRD leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRD?
▼

Per IRD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001228627), Opus Genetics Inc. generated $14.2M in revenue (+29.1% YoY), -$49.6M in net income, and -$35.3M in free cash flow against $50.2M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.70 (-0.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510023
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (3)Whales (4)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.7% Base Target
$7 Bull$3 Base$2 Bear
📬 FREE IRD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY IRD SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (35% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)

FRED Regime × Technicals: 37% of 52W Range • RSI-14 at 40 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$4.24-5.4% Next Q
Q2 (-2Q)
28
Grade E$4.01-13.7% Next Q
Q3 (-1Q)
26
Grade E$3.46+6.9% Next Q
Current
23
Grade E$3.70-11.1% Hist 90D α
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IRD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IRD currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.45) and Max Pain ($3.89) forces dealer call-delta covering toward $7.42.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 23%NO 77%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why IRD Stock advanced +0.82% Today — RQD Quant Desk Flash

Opus Genetics Inc. (IRD) advanced +0.82% to $3.70, trading at 37% of its 52-week range ($1.7 – $7.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 37% of its 52-week range ($1.7 – $7.07) with RSI-14 at 40 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.70 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IRD Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRD)

  • ✓Walkthrough of IRD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IRD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.12%📐 HORIZONTAL RANGE
2026-11-03O $3.65H $3.70L $3.65C $3.70VOL 1.02M
RES: $8.48SUP: $3.19SMA50: $4.45SMA200: $4.20
$7.38$6.10$4.81$3.53$2.24RES $8.48SUP $3.19$3.702026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRD Butterfly Map → + Track IRD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +29.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IRD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRD)

Health Care Rank #945 of 1015 ⚔️ BNTC vs IRD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRD vs. BNTC, PRLD, VOGX, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Opus Genetics Inc. (IRD) ranks #945 by composite RQD confidence (23/100, grade E) and #513 by equity capitalization ($305.3M). Within this direct 5-issuer industry benchmark cohort, IRD leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with IRD at 23/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IRD ACTIVE
Opus Genetics Inc.
E 23/100 — — -35.0% +0.82% $305.3M Benchmark Subject
BNTC
Benitec Biopharma Inc.
E 30/100 — — -35.0% -2.86% $304.9M /bntc-vs-ird →
PRLD
Prelude Therapeutics Incorporated
E 33/100 — — -35.0% -1.03% $309.6M /prld-vs-ird →
VOGX
Vogenx Inc
D 45/100 — — — +2.42% $300.8M /vogx-vs-ird →
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -2.61% $311.9M /enta-vs-ird →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001228627 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Opus Genetics Inc. (IRD) reported GAAP revenue of $14.2M (+29.1% vs. FY2024 revenue of $11.0M , and -25.5% cumulative change since FY2023) , GAAP net income of -$49.6M, operating cash flow of -$35.3M, and free cash flow of -$35.3M (-37.8% YoY). On the balance sheet, IRD closed FY2025 with $50.2M in total assets against $1.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $14.2M -$49.6M -$35.3M -$35.3M $50.2M $1.1M
FY2024 (FY) 2024-12-31 $11.0M -$57.5M -$25.6M -$25.6M $36.9M $0
FY2023 (FY) 2023-12-31 $19.0M -$10.0M -$1.1M -$1.1M — —

3. IRD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Opus Genetics Inc. (NASDAQ: IRD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $3.70 (+0.82% 1D, market cap $305.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IRD ranks #945 in composite RQD confidence.

How does IRD compare to BNTC and PRLD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRD carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $304.9M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, IRD leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRD?

Per IRD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001228627), Opus Genetics Inc. generated $14.2M in revenue (+29.1% YoY), -$49.6M in net income, and -$35.3M in free cash flow against $50.2M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRD last traded at $3.70 (+0.82% on volume of 878,222 shares), positioning the stock -16.85% below its 50-day simple moving average ($4.45) and -11.90% below its 200-day simple moving average ($4.20). Across its 52-week range of $1.70 to $7.07, IRD sits at the 37.2% percentile with a 14-day RSI of 40.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.24 to $4.16).

Direct Sub-Reports: IRD RQD Cockpit IRD 12M Forecast IRD Earnings & Move IRD Dividends & DRIP IRD Insiders & 13F IRD Whale Options IRD Profit Sankey IRD News & Why
ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ SEC XBRL & RQD VERIFIED

IRD — Opus Genetics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Opus Genetics Inc. (IRD) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.70 (+0.82% 1D, market capitalization $305.3M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -11.61%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 0.07x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Opus Genetics Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The source data describes the company with a market capitalization of $0.3B. Revenue of $14.2M is reported for FY 2025 .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Opus Genetics Inc. (IRD) reported $14.2M in annual revenue (up from $11.0M in FY2024, +29.1% YoY) and -$49.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.0M revenue, -$10.0M net income) through FY2025, IRD scaled operating cash flow to -$35.3M and free cash flow to -$35.3M, backed by $50.2M in total assets against $1.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.61% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.70 – $7.07 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream supply-chain links are recorded for IRD, and no sector correlation or proprietary signal links are available in the source. Accordingly, specific upstream dependencies, downstream customers, and 2nd-order bottlenecks are — The only cross-company reference in the news set is the MR-141 presbyopia discussion linking IRD and Viatris (VTRS); the nature and magnitude of that linkage is — beyond the headline itself.

  • Key Question #1: Can IRD sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $14.2M and free cash flow of -$35.3M, how will capital allocation balance growth reinvestment against $1.1M in total debt?
  • Key Question #3: How sensitive is IRD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IRD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Opus Genetics Inc. (IRD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IRD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IRD Bull vs. Bear Conversation Board — What's Your Call at $3.70?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IRD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $4.44 (+21.0%)
📌 Pinned Debate

Revenue grew from $11.0M in FY 2024 to $14.2M in FY 2025 while the balance sheet carries only $1.1M of debt against $45.1M of cash.

Revenue grew from $11.0M in FY 2024 to $14.2M in FY 2025 while the balance sheet carries only $1.1M of debt against $45.1M of cash.. When you look under the hood at IRD, Fundamental Cash Engine is 1/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (4/20) has been quietly accumulating below $7.07. My 12M target is $4.44.

RetailWhale_TX 🐂 BULL

Both sides have a point here — IRD's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $3.16 (-13.9%)
Spot @ $3.67

Free cash flow of -$35.3M, ROIC of -35%, and an Altman Z-Score of 0.2 signal that current operations are consuming capital with distres

Careful chasing IRD at $3.67. Free cash flow of -$35.3M, ROIC of -35%, and an Altman Z-Score of 0.2 signal that current operations are consuming capital with distress-level forensic readings.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.16 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%